Tags

Type your tag names separated by a space and hit enter

Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Breast. 2013 Oct; 22(5):958-63.B

Abstract

BACKGROUND

The aim of this study was to evaluate the significance of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for speculating the malignant level and prognostic value of operable breast cancers.

METHODS

Of 578 consecutive patients with primary invasive breast cancer who underwent curative surgery between 2005 and 2010, 311 patients (53.8%) who received FDG-PET/CT before initial therapy were examined.

RESULTS

Receiver operating characteristics (ROC) curve analysis showed the cutoff value of the maximum standardized uptake value (SUVmax) to predict cancer recurrence was 3.8 in all patients and 8.6 in patients with the triple-negative subtype, respectively. In all patients, 3-year DFS rates were 98.8% for patients with a tumor of SUVmax ≤ 3.8 and 91.6% for patients with a tumor of SUVmax > 3.8 (p < 0.001). High value of SUVmax was significantly associated with large tumor size (p < 0.001), lymph node metastasis (p = 0.040), high nuclear grade (p < 0.001), lymphovascular invasion (p = 0.032), negative hormone receptor status (p < 0.001), and positive HER2 status (p = 0.014). Based on the results of multivariate Cox analysis in all patients, high SUVmax (p = 0.001) and negative hormone receptor status (p = 0.005) were significantly associated with poor prognosis. In patients with triple-negative subtype, 3-year DFS rates were 90.9% for patients with a tumor of SUVmax ≤ 8.6 and 42.9% for patients with a tumor of SUVmax > 8.6 (p = 0.002), and high SUVmax was the only significant independent prognostic factor (p = 0.047).

CONCLUSION

FDG-PET/CT is useful for predicting malignant behavior and prognosis in patients with operable breast cancer, especially the triple-negative subtype.

Authors+Show Affiliations

Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima 734-0037, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23756383

Citation

Ohara, Masahiro, et al. "Role of FDG-PET/CT in Evaluating Surgical Outcomes of Operable Breast Cancer--usefulness for Malignant Grade of Triple-negative Breast Cancer." Breast (Edinburgh, Scotland), vol. 22, no. 5, 2013, pp. 958-63.
Ohara M, Shigematsu H, Tsutani Y, et al. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. Breast. 2013;22(5):958-63.
Ohara, M., Shigematsu, H., Tsutani, Y., Emi, A., Masumoto, N., Ozaki, S., Kadoya, T., & Okada, M. (2013). Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. Breast (Edinburgh, Scotland), 22(5), 958-63. https://doi.org/10.1016/j.breast.2013.05.003
Ohara M, et al. Role of FDG-PET/CT in Evaluating Surgical Outcomes of Operable Breast Cancer--usefulness for Malignant Grade of Triple-negative Breast Cancer. Breast. 2013;22(5):958-63. PubMed PMID: 23756383.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. AU - Ohara,Masahiro, AU - Shigematsu,Hideo, AU - Tsutani,Yasuhiro, AU - Emi,Akiko, AU - Masumoto,Norio, AU - Ozaki,Shinji, AU - Kadoya,Takayuki, AU - Okada,Morihito, Y1 - 2013/06/10/ PY - 2013/01/30/received PY - 2013/05/02/revised PY - 2013/05/09/accepted PY - 2013/6/13/entrez PY - 2013/6/13/pubmed PY - 2014/5/16/medline KW - AUC KW - Breast cancer KW - CT KW - DFS KW - ER KW - FDG-PET KW - HER2 KW - IDC KW - PET/CT KW - PgR KW - Prognosis KW - ROC KW - SUV(max) KW - Triple-negative breast cancer KW - [18F]-fluoro-2-deoxyglucose-positron emission tomography KW - area under the curve KW - computed tomography KW - disease-free survival KW - estrogen receptor KW - human epidermal growth factor receptor type 2 KW - invasive ductal carcinoma KW - maximum standardized uptake value KW - progesterone receptor KW - receiver operating characteristic SP - 958 EP - 63 JF - Breast (Edinburgh, Scotland) JO - Breast VL - 22 IS - 5 N2 - BACKGROUND: The aim of this study was to evaluate the significance of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for speculating the malignant level and prognostic value of operable breast cancers. METHODS: Of 578 consecutive patients with primary invasive breast cancer who underwent curative surgery between 2005 and 2010, 311 patients (53.8%) who received FDG-PET/CT before initial therapy were examined. RESULTS: Receiver operating characteristics (ROC) curve analysis showed the cutoff value of the maximum standardized uptake value (SUVmax) to predict cancer recurrence was 3.8 in all patients and 8.6 in patients with the triple-negative subtype, respectively. In all patients, 3-year DFS rates were 98.8% for patients with a tumor of SUVmax ≤ 3.8 and 91.6% for patients with a tumor of SUVmax > 3.8 (p < 0.001). High value of SUVmax was significantly associated with large tumor size (p < 0.001), lymph node metastasis (p = 0.040), high nuclear grade (p < 0.001), lymphovascular invasion (p = 0.032), negative hormone receptor status (p < 0.001), and positive HER2 status (p = 0.014). Based on the results of multivariate Cox analysis in all patients, high SUVmax (p = 0.001) and negative hormone receptor status (p = 0.005) were significantly associated with poor prognosis. In patients with triple-negative subtype, 3-year DFS rates were 90.9% for patients with a tumor of SUVmax ≤ 8.6 and 42.9% for patients with a tumor of SUVmax > 8.6 (p = 0.002), and high SUVmax was the only significant independent prognostic factor (p = 0.047). CONCLUSION: FDG-PET/CT is useful for predicting malignant behavior and prognosis in patients with operable breast cancer, especially the triple-negative subtype. SN - 1532-3080 UR - https://www.unboundmedicine.com/medline/citation/23756383/Role_of_FDG_PET/CT_in_evaluating_surgical_outcomes_of_operable_breast_cancer__usefulness_for_malignant_grade_of_triple_negative_breast_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0960-9776(13)00106-9 DB - PRIME DP - Unbound Medicine ER -